In summary, these findings highlight the therapeutic potential of myeloid-specific Atg16l1 in alleviating inflammatory signaling, hepatocyte apoptosis, and HSCs activation, thereby presenting a promising avenue for intervention in liver fibrosis. This evidence concerns the gene ATG16L1 and Hepatic fibrosis.